BT1 Stock Overview
BioSenic S.A., a biotech company, focuses on developing clinical assets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0059 |
| 52 Week High | €0.12 |
| 52 Week Low | €0.0056 |
| Beta | 0 |
| 1 Month Change | -63.58% |
| 3 Month Change | -70.50% |
| 1 Year Change | -94.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| BT1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -2.9% | 1.9% |
| 1Y | -94.6% | -25.4% | 5.9% |
Return vs Industry: BT1 underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: BT1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| BT1 volatility | |
|---|---|
| BT1 Average Weekly Movement | 74.6% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BT1's share price has been volatile over the past 3 months.
Volatility Over Time: BT1's weekly volatility has decreased from 88% to 75% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | François Rieger | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| BT1 fundamental statistics | |
|---|---|
| Market cap | €2.72m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BT1 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
Jun 06, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BT1 perform over the long term?
See historical performance and comparison